Research & Development: Page 63
-
PharmaVoice Team/PharmaVoice
Germany: A Market for Clinical Research
G ermany is a pre-eminent pharmaceutical market. In 2008, for example, the German pharmaceutical industry comprised 243 companies, employed 126,000 people, and generated EUR 41.5 billion ($53.8 billion) in revenue, according to Germany Trade & Invest, a German investment agency. Germany is th...
By Kim Ribbink • Feb. 27, 2012 -
PharmaVoice Team/PharmaVoice
Payers Play Larger Role In PostLaunch Strategies
The focus of postlaunch activities has changed dramatically in just a few short years. Robin Robinson Due to the increased power of payers and managed care companies, Phase IV studies have become more imperative to sustaining a successful postlaunch campaign. Companies have had to reprioritize th...
By Robin Robinson • Feb. 26, 2012 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Rising Costs Are Top of Mind in Phase III
The good news: more drugs are entering Phase III trials. The bad news: clinical trial costs continue to rise. The number of drugs in Phase III development in 2011 increased by 13%, representing the largest year-over-year improvement seen, according to Citeline’s 2011 Annual Review of Trends in Ph...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Creating the Message in Phase II Trials
Decisions made in Phase II trials can have an impact on the development and marketing program for new products, and experts say Phase II is becoming a critical stage for planning the potential launch and marketing of products. Bringing agencies in earlier in the process makes a lot of sense, says...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
New Models for Early Development
The number of drugs entering Phase I fell 47% and the number of drugs entering Phase II trials fell 53%, according to 2011 Pharmaceutical R&D Factbook complied by CMR International. Industry experts say there is a trend toward conducting fewer, more complex early-phase studies that often incl...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Achieving Value from Discovery and Preclinical Endeavors
The need to increase value and productivity throughout the development process has never been more critical. R&D expenditure continued to drop in 2010 to an estimated three-year low of $68 billion, and drug success rates continue to show the declining trends of the past decade, according to t...
By Denise Myshko • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Molecule to Market - Along the Continuum
According to the most recent report from Tufts Center for the Study of Drug Development, it still takes about 10 to 15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. Only one ...
By Taren Grom • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Dr. Anders EKBLOM Dr. Briggs MORRISON AstraZeneca Bolsters R&D Leadership Global pharmaceutical company AstraZeneca has tapped Anders Ekblom, M.D., to build and lead the science and technology integration office within the company’s R&D organization. In addition to th...
By Carolyn Gretton • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: Kantar Health Focuses on Cancer Patients’ Healthcare Decision-Making Aerpio Therapeutics Makes Debut In other news… Inspiration Biopharmaceuticals Moves Corporate Headquarters AROUND THE GLOBE Kantar Health, a healthcare-fo...
By Carolyn Gretton • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Long-Term Planning Tactics Key to Maintaining Portfolio Health Sidebar: Groups Responsible for Aligning Brand and Corporate Strategy Therapeutic Fast Trax… Other market insights… Brand Positioning Should Balance PR, RO...
By Taren Grom • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
UpFront
Awards… » Invivodata Co-Founder wins Carnegie Science Awards Invivodata Co-founder and Chief Science Officer, Dr. Saul Shiffman has been recognized by the Carnegie Science Center as an honorable mention in the Entrepreneur Category of its 2012 Carnegie Science Awards. Dr. Shiffman is being ...
By Taren Grom • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
From Molecule through Market… the vision is clear — to be successful pharmaceutical companies and their valued development partners need to understand the underlying challenges, trends, and opportunities that each molecule, compound, diagnostic, or biotech product faces as it progresses along the...
By Taren Grom • Feb. 26, 2012 -
PharmaVoice Team/PharmaVoice
Outsourcing: Enhance, Support, Grow
You cannot do today’s job with yesterday’s methods and be in business tomorrow." The wise words of Nelson Jackson should be the driving force behind every outsourcing partnership today. Implementing innovative strategies through outsourcing helps pharmaceutical companies meet the changing demands...
By Erin Neary and Dennis McLoughlin • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Commercialization - Decisions, Decisions, Decisions
In recent years, the research and development landscape in the pharmaceutical industry has radically changed. The search for the next big blockbuster has been replaced by the search for medicines targeted toward specific patient subpopulations or toward diseases with high unmet medical need to ma...
By Dr. Michael Ackerman • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Pharmaceutical Call Centers Build relationships with Healthcare Providers and Patients
Pharmaceutical, biotechnology, and medical device companies have a significant need to build relationships with prescribers and patients. However, these audiences have very different needs that require companies to take varying approaches to communicate effectively with them. Healthcare providers...
By Lou Shapiro • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
The Emergence of Strategic Outsourcing in Clinical Supply Chain Management
Ten years ago few biopharmaceutical industry professionals could have predicted how broadly the landscape for outsourcing would change by 2012. Most companies were outsourcing in a tactical, project-by-project manner and utilizing dozens of providers across functional areas. Some were moving to a...
By Robert Dunlop • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Why Outsourcing Patient Enrollment to a Specialist Makes Sense
Richard Malcolm, Ph.D., CEO, Acurian Disruptive change is needed in clinical trial management, an industry where inadequate enrollment has become the biggest driver of wasted dollars. The cost of patient enrollment is now the single largest part of the total trial budget, representing 32% of the ...
By Richard Malcolm • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Help from The Outside
Help from the Outside Showcase Feature: Outsourcing Carolyn Gretton As life-sciences companies look to improve operational efficiencies within their organizations, they are increasingly reducing the number of activities that they would categorize as core competencies and outsourcing them to thir...
By Carolyn Gretton • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Trends, Challenges, and Best Practices of Global Product Launches
Companies both large and small are expanding their global launch approach. Robin Robinson With all the variances and complexities involved in launching a product globally, especially around regulatory and approval requirements within various regions across countries, one could argue that there is...
By Robin Robinson • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
C-Suite CROs
Insights from the C-Suite: Contract Research Organizations CRO growth continues to outpace other sectors. Frost &?Sullivan estimates that the CRO market earned revenue of $11.43 billion in 2010 and estimates that the sector will top $20.09 billion in 2017. According to a recent Frost & Su...
By Taren Grom • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Transformative Leadership
Taren Grom Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company, is leading her company to achieve an audacious goal: curing cancer. We are what we repeatedly do…excellence, then, is not so much an act, but a habit." This Aristotle quote is one of Deborah Dunsire, M.D...
By Taren Grom • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
Creating Jobs in the Industry Safi Bahcall, Ph.D., CEO, Synta Pharmaceuticals, discusses how the extension of the R&D tax credit for life-sciences companies can accelerate job creation. PV: What do you think employment within the industry will look like in 2012? Bahcall: As the U.S. economy...
By Safi Bahcall • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Aaron BERG Essentialis Names CEO Essentialis, a pharmaceutical company focused on a novel medicine for the treatment of cardiovascular and metabolic disease, has promoted Aaron Berg to CEO, fro...
By Carolyn Gretton • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry By Carolyn Gretton Life-Sciences Companies Face Increased Complexity in Aggregate Spend Tracking and Reporting Trend: Aggregate spend mandates within the life-sciences industry are continuing to evolve in 2012 amid ongoing cha...
By Carolyn Gretton • Jan. 27, 2012 -
PharmaVoice Team/PharmaVoice
What's New
New healthcare-related products, services, and companies By Carolyn Gretton New Alliance Promotes Trust in Online Physician Research Trend: Market research organizations, which base many critical decisions on insights from online physician panels, are taking collective action to ensure the integ...
By Carolyn Gretton • Jan. 26, 2012
Previous
